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doi:10.1016/j.ejvs.2008.06.026Abstract Objective: To determine which covariates predisposed to deep venous occlusion
(DVO) after ultrasound-guided sclerotherapy (UGS) for varicose veins.
Design: Ultrasound scans before and at 3 to 7 days after UGS to detect post-procedure deep
venous occlusion.
Materials: A consecutive series of 1931 treatment sessions in 852 patients treated by a tech-
nique for UGS.
Methods: Ultrasound examination of the full length of axial deep veins above and below knee
before and soon after every procedure. Crude c2 analysis of all covariates allowed selection of
those that showed apparent significant influence. Logistic regression analysis of these then
determined which independently predisposed to post-procedure deep venous occlusion.
Results: Deep venous occlusion was only observed after UGS using foamed sclerosant and
occurred following 28 treatment sessions. No significant difference for risk of deep venous
occlusion was observed for patient characteristics or which veins were treated. Logistic regres-
sion analysis showed significant independent increased risk in a limb from using highly diluted
or undiluted sclerosant (OR 0.55; 95% CI 0.19 to 1.59 for 0.6e1.0% solution, OR 10.45; 95% CI
3.12 to 34.99 for 2-2.3% and OR 0.36; 95% CI 0.07 to 1.74 for 3% solution), treating veins 5 mm
diameter (OR 3.70; 95% CI 1.23 to 11.13) and injecting 10 ml of foamed sclerosant for a limb
(OR 3.64; 95% CI 1.21 to 10.90).
Conclusions: The risk of deep venous occlusion after UGS in this series was lower when using
highly diluted or undiluted sclerosant, when treating veins less than 5 mm in diameter and
when restricting the volume of foam injected to less than 10 ml.
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Factors Affecting the Risk of Deep Venous Occlusion 603Introduction saphenous veins grouped together, small saphenous andUltrasound-guided sclerotherapy (UGS) is now widely used
to treat superficial venous disease. Its efficacy has been
demonstrated but post-procedure ultrasound surveillance
has also shown that it can be complicated by deep venous
occlusion (DVO).1 This paper analyses factors relating to the
patients, veins and technique that could predispose to the
complication in a consecutive series of 1931 treatment
sessions for UGS in 852 patients.
Materials and Methods
Patient characteristics
Characteristics of patients treated by UGS in this study have
been described previously.1 One surgeon (KM) was respon-
sible for all procedures performed between January 1999
and April 2007. There were 1931 treatment sessions for
1430 vein systems in 1225 legs of 852 patients. The numbers
of treatment sessions according to characteristics of the
patients, legs and veins are shown in Table 1. The majority
were female and a wide age range was treated. UGS was
either the first procedure chosen, was performed for recur-
rent varicosities after previous surgery for the veins, or was
required to treat distal saphenous veins or tributaries at
about 2e3 weeks after endovenous laser therapy. The veins
treated were the great saphenous and/or anterior accessoryTable 1 Characteristics of patients, legs and veins treated, with











Clinical CEAP C2-3 1795
C4-6 136
Previous treatment No previous treatment 1273
Prior Surgery 186
Prior Endovenous Laser 472
Number of treatment sessions First 1596
Second 279
Third or more 56
Deep venous reflux No 1907
Yes 24
Vein Great saphenous 981
Small saphenous 296
Tributaries only 654
Diameter 4 mm 970
5 mm 378
6 mm 352
7 mm 223thigh extension veins, or tributaries alonewithout saphenous
reflux. Representative diameters of the principal veins were
measured by ultrasound before treatment. Only one session
was required for adequate treatment for the larger propor-
tion of patients, but a second session about one week later
was required for some and three or more sessions for a small
number.
Treatment technique
The numbers of treatment sessions according to variations
in treatment techniques are shown in Table 2. No anticoa-
gulation was given prior to June 2002 after which it was
decided to give a single prophylactic dose of 40 mg of enox-
aparin sodium immediately prior to all procedures. The
sclerosants used were 3% polidocinol or 3% sodium tetra-
decyl sulphate (STS) according to the treating doctor’s
preference at the time. Liquid sclerosants were used until
November 2000 and foam UGS for all subsequent
procedures. These were injected undiluted for all liquid
sclerosant procedures but were frequently diluted with
saline to various concentrations down to 0.6% for foam
UGS according to the amount of foam anticipated to be
required. Foam was made by a variation of the Tessari tech-
nique2 mixing two parts of fluid with three parts of air
between two syringes. The volume of liquid sclerosant
injected at each session ranged from 2 to 10 (median 5)
ml. The volume of foam sclerosant injected at each sessionnumbers of sessions, prevalence of DVO and univariate odds
r Sessions Prevalence DVO OR 95% CI P-value
2.6% 2.64 1.05 6.63 0.039
1.1% 1.0
0.9% 0.75 0.17 3.26 0.695
1.3% 1.11 0.31 3.95 0.870
1.1% 1.0
2.6% 2.52 0.83 7.67 0.104
1.4% 1.29 0.29 5.78 0.742
1.2% 1.0
1.7% 1.36 0.66 2.80 0.411
1.5% 1.0
1.5% 1.02 0.24 4.27 0.984
1.2% 1.0
2.2% 1.84 0.60 5.65 0.285
1.9% 1.63 0.67 3.96 0.282
1.3% 1.0
2.2% 1.65 0.65 4.17 0.292




0.7% 0.44 0.10 1.95 0.278
1.7% 1.10 0.49 2.50 0.819
0.8% 1.0
2.4% 3.92 1.32 11.65 0.014
2.3% 3.73 1.29 10.78 0.015
2.2% 3.68 1.12 12.15 0.032
Table 2 Treatment techniques, with numbers of sessions, prevalence of DVO and univariate odds ratio (OR) for DVO
Variable Value Number Sessions Prevalence DVO OR 95% CI P-value
Pre-procedure LMWH Given 904 1.7% 1.32 0.61 2.84 0.481
Not given 1027 1.3% 1.0
Sclerosant Sodium tetradecyl sulphate 1706 1.2% 1.0
Polidocinol 225 3.6% 3.11 1.33 7.24 0.009
Preparation sclerosant Foam 1835 1.5%
Liquid 96 0.0%
Concentration of sclerosant 0.6e1.0% 565 1.4% 1.02 0.42 2.49 0.958
1.2e1.5% 940 1.4% 1.0
2.0e2.5% 31 16.1% 13.71 4.83 38.94 <0.001
3.0% 395 0.5% 0.36 0.09 1.46 0.154
Site of injection Saphenous vein 1043 1.0% 1.0
Tributary 888 2.0% 2.14 0.97 4.71 0.060
Level of injection Above knee 558 0.7% 0.43 0.14 1.28 0.130
Below knee 1147 1.7% 1.0
Above and below knee 226 2.2% 1.34 0.49 3.65 0.565
Volume injected <10ml 1227 0.6% 1.0
10ml 704 3.0% 5.35 2.25 12.73 <0.001
604 K.A. Myers, D. Jolleyranged from 2 to 45 (median 5) ml. Sclerosant was injected
through tributaries or into saphenous veins according to
which appeared to be the best way to fill the veins. The
policy was to inject diseased veins as far distal as possible
with a second injection if needed to fill the veins resulting
in injection below knee, above knee or both.
Ultrasound Surveillance
All ultrasound examinations in this study were performed
by specialist vascular sonographers attached to the unit.
Selection of suitable patients was made on the basis of pre-
procedure ultrasound scanning of all superficial and axial
deep veins. Prior to treatment, segments of superficial
veins that showed reflux were documented and all axial
deep veins were examined to determine whether there
were any segment that showed reflux and/or occlusion.
Scans were repeated at 3 to 7 days after each treatment
session to confirm occlusion of treated superficial veins,
detect persistent superficial veins that might need further
treatment and to examine all axial deep veins above and
below knee for segments of occlusion that were not present
before the procedures.
Statistical Analysis
We compared characteristics of treated veins using contin-
gency table analysis, adjusted for clustering based on
patient. Odds ratios, with 95% confidence intervals, and
P-values were computed using logistic regression with stan-
dard errors based on Huber-White sandwich estimates of
intra-patient correlation (StataCorp, 2005). We developed
a predictive model for deep venous occlusion prevalence
by first identifying all statistically significant (P< 0.05)
univariate predictors, and then combining these into
a single multivariable logistic model, from which we
inferred a short list of independent, unconfounded predic-
tors of the risk of deep venous occlusion.Results
There were no segments of deep venous occlusion detected
prior to treatment. Deep venous occlusions were detected
after 28 treatment sessions (1.45%). Their site according to
the veins treated is shown in Table 3. There were 16 treat-
ment sessions that led to segments of total occlusion of
posterior tibial veins and 12 sessions with partial occlusion
of above-knee axial deep veins. All occlusions appeared to
be asymptomatic and none was known to progress to clin-
ical venous thromboembolic events. There was one further
patient who suffered clinical pulmonary embolism without
evidence of deep venous occlusion.
The results of univariate c2 analysis for significant covari-
ates according to patient characteristics and treatment
techniques are shown in Tables 1 and 2. There was apparent
significant increased risk of deep venous occlusion for males
compared to females, for polidocinol compared to STS, for
medium dilution of foamed sclerosant, for vein diameters
5 mm and for volumes of foam injected 10 ml. There
was no significant increased risk according to age, side, clin-
ical CEAP classification, treatment for primary or recurrent
veins or for residual veins after endovenous laser therapy,
presence or absence of pre-treatment deep venous reflux,
the veins treated, whether it was the first or a repeat UGS
session, the level of injection above or below knee, or
whether or not an injection of low molecular weight heparin
was given.
The results for multivariable logistic regression analysis
for all covariates shown by c2 analysis to possibly influence
results are shown in Table 3. The persistent significant cova-
riates independently predicting increased risk of deep
venous occlusion were medium diluted concentrations of
sclerosant compared to highly diluted or undiluted sclero-
sant (OR 0.55; 95% CI 0.19 to 1.59 for 0.6e1.0% solution, OR
10.45; 95% CI 3.12 to 34.99 for 2e2.3% and OR 0.36; 95% CI
0.07 to 1.74 for 3% solution), treating veins5 mm diameter
(OR 3.70; 95% CI 1.23 to 11.13) and injecting 10 ml of
foamed sclerosant for a limb (OR 3.64; 95% CI 1.21 to 10.90).
Table 3 Results of multivariable logistic regression analyses to identify independent predictors of DVO risk.
Level Model 1 Model 2
OR 95% CI P-value OR 95% CI P-value
Sex
Male 1.99 0.84 4.69 0.117
Female 1.00
Scleroscant
Sodium tetradecyl sulphate 1.00
Polidocinol 1.75 0.58 5.26 0.320
Concentration of scleroscant
0.6%e1% 0.55 0.19 1.59 0.271 0.46 0.17 1.28 0.136
1.2%e1.5% 1.00 1.00
2%e2.3% 10.45 3.12 34.99 <0.001 12.10 3.86 37.94 <0.001
3% 0.36 0.07 1.74 0.204 0.36 0.08 1.61 0.183
Vein diameter (mm)
4 1.00 1.00
5 3.70 1.23 11.13 0.020 3.89 1.29 11.71 0.016
6 3.20 0.94 10.94 0.064 3.69 1.10 12.34 0.034
7 2.88 0.79 10.43 0.108 3.13 0.83 11.74 0.092
Volume injected
<10 ml 1.00 1.00
>Z10 ml 3.64 1.21 10.90 0.021 4.25 1.49 12.10 0.007
Model 1 includes all variables found as significant from univariable analyses; Model 2 includes only those significant in Model 1.
Factors Affecting the Risk of Deep Venous Occlusion 605Discussion
In this study, deep venous occlusion was only observed after
UGS with foamed sclerosant although the numbers treated
by liquid UGS were relatively small. The larger proportion
occurred in below-knee posterior tibial veins but partial
occlusions of above-knee axial deep veins were detected. It
was difficult to know whether the occlusions were due to
secondary deep vein thrombosis or to foam ‘‘sclerus’’
entering the deep veins. It appeared that none of the
events led to clinical venous thromboembolic sequelae.
The frequency of deep vein occlusion was higher than
previously reported 3,4 but this is likely to be due to the policy
of scanning the limbs soon after every treatment session.
Crude c2 analysis suggested that the risk might be increased
in males and for polidocinol rather than STS but this did not
prove to be significant with logistic regression analysis. There
was no significant influence for risk frompatient or limb char-
acteristics nor several other aspects relating to treatment
technique. Nor was the risk reduced by giving a single dose
of low molecular weight heparin and this practice has now
been abandoned. Ankle exercise immediately following
injection of foam has been suggested as a useful method of
preventing deep vein thrombosis after foam sclerotherapy
but was not used in this clinical series.
We had previously reported that the long-term success
rate was significantly improved by using a 1.5% solution of
sclerosant for foam UGS.1 However, this study shows that
the risk of deep venous occlusion is highest for medium
concentrations and lowest for 0.6e1% dilution or undiluted
3% sclerosant. Reasons for these findings are not known
although Parsi and colleagues have shown that varying the
concentration of liquid sclerosants in vitro influence
whether they are procoagulant or anticoagulant.5 The
second significant finding was that risk was increased bymore than threefold for veins treated that were 5 mm
diameter and it may be best to consider other forms of
treatment for large diameter veins. The third significant
influence shown by logistic regression analysis was that
injecting 10 ml of foam in a limb resulted in a more
than threefold increased risk for deep venous occlusion. A
recent European Consensus group has recommended that
the volume used in one session should be less than 10 ml 6
and results from the present study support this opinion.
Accordingly, this study shows that UGS has a low risk of
causing deep venous occlusion but that the risk is further
reduced by considering the concentration of sclerosant, by
treating veins less than 5 mm diameter and by using less
than 10 ml foam at any treatment session.
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